Famciclovir: A focus on efficacy and safety

Expert Opinion on Drug Safety

Volumn 9, Issue 4, 2010, Pages 643-658

  Mubareka, Samira ^a   Leung, Victor ^b   Aoki, Fred Y ^c   Vinh, Donald C ^b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

antivirals; famciclovir; guanosine analogue; hepatitis B virus; herpes simplex virus; penciclovir; protease inhibitor; varicella zoster virus

Indexed keywords

ACICLOVIR; CIDOFOVIR; FAMCICLOVIR; FOSCARNET; LAMIVUDINE; METHOTREXATE; PENCICLOVIR; PLACEBO; QUININE; RALOXIFENE; VALACICLOVIR; 2 AMINOPURINE; ANTIVIRUS AGENT;

ABDOMINAL PAIN; ANTIVIRAL RESISTANCE; CHICKENPOX; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; FEVER; FURUNCULOSIS; GASTROINTESTINAL SYMPTOM; GENITAL TRACT INFECTION; HEPATITIS B; HERPES LABIALIS; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; INFECTION; INSOMNIA; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; REVIEW; ANALOGS AND DERIVATIVES; DRUG EFFECTS; FEMALE; HEPATITIS B VIRUS; HERPESVIRIDAE INFECTIONS; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SIMPLEXVIRUS; TREATMENT OUTCOME; VARICELLA ZOSTER VIRUS;

2-AMINOPURINE; ANTIVIRAL AGENTS; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 3, HUMAN; HUMANS; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SIMPLEXVIRUS; TREATMENT OUTCOME;

EID: 77953770192     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.2010.485189     Document Type: Review

References (110)

1. Aoki FY. Contemporary antiviral drug regimens for the prevention and treatment of orolabial and anogenital herpes simplex virus infection in the normal host: four approved indications and 13 off-label uses. Can J Infect Dis 2003;14(1):17-27
2. Champness JN, Bennett MS, Wien F, et al. Exploring the active site of herpes simplex virus type-1 thymidine kinase by X-ray crystallography of complexes with aciclovir and other ligands. Proteins 1998;32(3):350-361
3. Pue MA, Benet LZ. Pharmacokinetics of famciclovir in man. Antiviral Chem Chemother 1993;4(Suppl 1):47-55
4. Earnshaw DL, Bacon TH, Darlison SJ, et al. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother 1992;36(12):2747-2757
5. Reardon JE. Herpes simplex virus type 1 and human DNA polymerase interactions with 2¢-deoxyguanosine 5¢-triphosphate analogues. Kinetics of incorporation into DNA and induction of inhibition. J Biol Chem 1989;264(32):19039-19044
6. Reardon JE, Spector T. Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate. J Biol Chem 1989;264(13):7405-7411
7. Bacon TH, Howard BA, Spender LC, Boyd MR. Activity of penciclovir in antiviral assays against herpes simplex virus. J Antimicrob Chemother 1996;37(2):303-313
8. Safrin S, Phan L. In vitro activity of penciclovir against clinical isolates of acyclovir-resistant and foscarnet-resistant herpes simplex virus. Antimicrob Agents Chemother 1993;37(10):2241-2243
9. Sarisky RT, Bacon TH, Boon RJ, et al. Profiling penciclovir susceptibility and prevalence of resistance of herpes simplex virus isolates across eleven clinical trials. Arch Virol 2003;148(9):1757-1769
10. Pelosi E, Mulamba GB, Coen DM. Penciclovir and pathogenesis phenotypes of drug-resistant Herpes simplex virus mutants. Antiviral Res 1998;37(1):17-28
11. Bae PK, Kim JH, Kim HS, et al. Intracellular uptake of thymidine and antiherpetic drugs for thymidine kinase-deficient mutants of herpes simplex virus type 1. Antiviral Res 2006;70(3):93-104
12. Bacon TH, Levin MJ, Leary JJ, et al. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev 2003;16(1):114-128
13. Wild K, Bohner T, Folkers G, Schulz GE. The structures of thymidine kinase from herpes simplex virus type 1 in complex with substrates and a substrate analogue. Protein Sci 1997;6(10):2097-2106
14. Sarisky RT, Quail MR, Clark PE, et al. Characterization of herpes simplex viruses selected in culture for resistance to penciclovir or acyclovir. J Virol 2001;75(4):1761-1769
15. Pardeiro M, Cuenca-Estrella M, Fernandez-Clua MA, et al. Characterisation of penciclovir resistant acyclovir sensitive herpes simplex virus type 2 isolated from an AIDS patient. J Med Virol 2004;73(1):60-64
16. Suzutani T, Ishioka K, De Clercq E, et al. Differential mutation patterns in thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 clones passaged in the presence of acyclovir or penciclovir. Antimicrob Agents Chemother 2003;47(5):1707-1713
17. Pue MA, Pratt SK, Fairless AJ, et al. Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers. J Antimicrob Chemother 1994;33(1):119-127
18. Andrei G, De Clercq E, Snoeck R. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir? Antiviral Res 2004;61(3):181-187
19. Boyd MR, Bacon TH, Sutton D. Antiherpesvirus activity of 9-(4-hydroxy- 3-hydroxymethylbut-1-yl) guanine (BRL 39123) in animals. Antimicrob Agents Chemother 1988;32(3):358-363
20. Moomaw MD, Cornea P, Rathbun RC, Wendel KA. Review of antiviral therapy for herpes labialis, genital herpes and herpes zoster. Expert Rev Anti Infect Ther 2003;1(2):283-295
21. Pue MA, Benet LZ. Pharmacokinetics of famciclovir in man. Antivir Chem Chemother 1993;4:47-55
22. Fowles SE, Pierce DM, Prince WT, Staniforth D. The tolerance to and pharmacokinetics of penciclovir (BRL 39,123A), a novel antiherpes agent, administered by intravenous infusion to healthy subjects. Eur J Clin Pharmacol 1992;43(5):513-516
23. Chong DY, Johnson MW, Huynh TH, et al. Vitreous penetration of orally administered famciclovir. Am J Ophthalmol 2009;148(1):38-42 e1
24. Saez-Llorens X, Yogev R, Arguedas A, et al. Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection. Antimicrob Agents Chemother 2009;53(5):1912-1920
25. Gill KS, Wood MJ. The clinical pharmacokinetics of famciclovir. Clin Pharmacokinet 1996;31(1):1-8
26. Maru MC, Fialkow RZ, Haria DM. Choreiform movements in dialysis patient taking valacyclovir and famciclovir. South Med J 2001;94(6):655
27. Htwe TH, Bergman S, Koirala J. Famciclovir substitution for patients with acyclovir-associated renal toxicity. J Infect 2008;57(3):266-268
28. Boike SC, Pue M, Audet PR, et al. Pharmacokinetics of famciclovir in subjects with chronic hepatic disease. J Clin Pharmacol 1994;34(12):1199-1207
29. Rashidi MR, Smith JA, Clarke SE, Beedham C. In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver. Drug Metab Dispos 1997;25(7):805-813
30. Baringer JR. Herpes simplex infections of the nervous system. Neurol Clin 2008;26(3):657-74, viii
31. Cunha BA, Eisenstein LE, Dillard T, Krol V. Herpes simplex virus (HSV) pneumonia in a heart transplant: diagnosis and therapy. Heart Lung 2007;36(1):72-78
32. Gooskens J, Templeton KE, Claas EC, et al. Quantitative detection of herpes simplex virus DNA in the lower respiratory tract. J Med Virol 2007;79(5):597-604
33. Cernik C, Gallina K, Brodell RT. The treatment of herpes simplex infections: an evidence-based review. Arch Intern Med 2008;168(11):1137-1144
34. Chauvin PJ, Ajar AH. Acute herpetic gingivostomatitis in adults: a review of 13 cases, including diagnosis and management. J Can Dent Assoc 2002 68(4):247-251
35. Spruance SL, Kriesel JD. Treatment of herpes simplex labialis. Herpes 2002;9(3):64-69
36. Rooney JF, Straus SE, Mannix ML, et al. Oral acyclovir to suppress frequently recurrent herpes labialis. A double-blind, placebo-controlled trial. Ann Intern Med 1993;118(4):268-272
37. Spruance SL, Bodsworth N, Resnick H, et al. Single-dose, patient-initiated famciclovir: a randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis. J Am Acad Dermatol 2006;55(1):47-53
38. Raborn GW, Grace MG. Recurrent herpes simplex labialis: selected therapeutic options. J Can Dent Assoc 2003 69(8):498-503
39. Hull C, Spruance S, Tyring S, Hamed K. Single-dose famciclovir for the treatment of herpes labialis. Curr Med Res Opin 2006;22(9):1699-1702
40. Bodsworth N, Fife K, Koltun W, et al. Single-day famciclovir for the treatment of genital herpes: follow-up results of time to next recurrence and assessment of antiviral resistance. Curr Med Res Opin 2009;25(2):483-487
41. Baker D, Eisen D. Valacyclovir for prevention of recurrent herpes labialis: 2 double-blind, placebo-controlled studies. Cutis 2003;71(3):239-242
42. Alster TS, Nanni CA. Famciclovir prophylaxis of herpes simplex virus reactivation after laser skin resurfacing. Dermatol Surg 1999;25(3):242-246
43. Silverman AK, Laing KF, Swanson NA, Schaberg DR. Activation of herpes simplex following dermabrasion. Report of a patient successfully treated with intravenous acyclovir and brief review of the literature. J Am Acad Dermatol 1985;13(1):103-108
44. Perkins SW, Sklarew EC. Prevention of facial herpetic infections after chemical peel and dermabrasion: new treatment strategies in the prophylaxis of patients undergoing procedures of the perioral area. Plast Reconstr Surg 1996;98(3):427-33;discussion 34-35
45. Spruance SL, Stewart JC, Freeman DJ, et al. Early application of topical 15% idoxuridine in dimethyl sulfoxide shortens the course of herpes simplex labialis: a multicenter placebo-controlled trial. J Infect Dis 1990;161(2):191-197
46. Spruance SL, Jones TM, Blatter MM, et al. High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrob Agents Chemother 2003;47(3):1072-1080
47. Spruance SL, Hill J. Clinical significance of antiviral therapy for episodic treatment of herpes labialis: exploratory analyses of the combined data from two valaciclovir trials. J Antimicrob Chemother 2004;53(5):703-707
48. Lin L, Chen XS, Cui PG, et al. Topical application of penciclovir cream for the treatment of herpes simplex facialis/labialis: a randomized, double-blind, multicentre, aciclovir-controlled trial. J Dermatol Treat 2002;13(2):67-72
49. Raborn GW, Martel AY, Lassonde M, et al. Effective treatment of herpes simplex labialis with penciclovir cream: combined results of two trials. J Am Dent Assoc 2002;133(3):303-309
50. Loveless M, HJ, Sacks SL. Famciclovir in the management of first-episode genital herpes. Infect Dis Clin Prac 1997;6(Suppl 1):S12-S6
51. Modi S, Van L, Gewirtzman A, et al. Single-day treatment for orolabial and genital herpes: a brief review of pathogenesis and pharmacology. Ther Clin Risk Manag 2008;4(2):409-417
52. Aoki FY. The continuing evolution of antiviral therapy for recurrent genital herpes: 1-day patient-initiated treatment with famciclovir. Herpes 2007;14(3):62-65
53. Douglas JM, Critchlow C, Benedetti J, et al. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med 1984;310(24):1551-1556 (Pubitemid 14117334)
54. Mindel A, Weller IV, Faherty A, et al. Prophylactic oral acyclovir in recurrent genital herpes. Lancet 1984;2(8394):57-59
55. Gold D, Corey L. Acyclovir prophylaxis for herpes simplex virus infection. Antimicrob Agents Chemother 1987;31(3):361-367 (Pubitemid 17027121)
56. Straus SE, Seidlin M, Takiff HE, et al. Double-blind comparison of weekend and daily regimens of oral acyclovir for suppression of recurrent genital herpes. Antiviral Res 1986;6(3):151-159
57. Sacks SL, Fox R, Levendusky P, et al. Chronic suppression for six months compared with intermittent lesional therapy of recurrent genital herpes using oral acyclovir: effects on lesions and nonlesional prodromes. Sex Transm Dis 1988;15(1):58-62
58. Goldberg LH, Kaufman R, Kurtz TO, et al.; Acyclovir Study Group. Long-term suppression of recurrent genital herpes with acyclovir. A 5-year benchmark. Arch Dermatol 1993;129(5):582-587
59. Mertz GJ, Eron L, Kaufman R, et al. Prolonged continuous versus intermittent oral acyclovir treatment in normal adults with frequently recurring genital herpes simplex virus infection. Am J Med 1988;85(2A):14-19
60. Diaz-Mitoma F, Sibbald RG, Shafran SD, et al. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group. JAMA. 1998;280(10):887-892
61. Wald A, Selke S, Warren T, et al. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sex Transm Dis. 2006;33(9):529-533
62. Bartlett BL, Tyring SK, Fife K, et al. Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: the RELIEF trial. J Clin Virol. 2008;43(2):190-195
63. Sacks SL. Famciclovir suppression of asymptomatic and symptomatic recurrent anogenital herpes simplex virus shedding in women: a randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-center trial. J Infect Dis. 2004;189(8):1341-1347
64. Leone P, Warren T, Hamed K, et al. Famciclovir reduces viral mucosal shedding in HSV-seropositive persons. Sex Transm Dis. 2007;34(11):900-907
65. Lebrun-Vignes B, Bouzamondo A, Dupuy A, et al. A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks. J Am Acad Dermatol. 2007;57(2):238-246
66. Sacks SL, Aoki FY, Diaz-Mitoma F, et al; Canadian Famciclovir Study Group. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. JAMA 1996;276(1):44-49
67. Sacks SL, Aoki FY, Martel AY, et al. Clinic-initiated, twice-daily oral famciclovir for treatment of recurrent genital herpes: a randomized, double-blind, controlled trial. Clin Infect Dis 2005;41(8):1097-1104
68. Chosidow O, Drouault Y, Leconte-Veyriac F, et al. Famciclovir vs aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial. Br J Dermatol 2001;144(4):818-824
69. Bodsworth N, Bloch M, McNulty A, et al. 2-day versus 5-day famciclovir as treatment of recurrences of genital herpes: results of the FaST study. Sex Health 2008;5(3):219-225
70. Aoki FY, Tyring S, Diaz-Mitoma F, et al. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2006;42(1):8-13
71. Abudalu M, Tyring S, Koltun W, et al. Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: a randomized, double-blind, comparative trial. Clin Infect Dis 2008;47(5):651-658
72. Vinh DC, Aoki FY. Famciclovir for the treatment of recurrent genital herpes: a clinical and pharmacological perspective. Expert Opin Pharmacother 2006;7(16):2271-2286
73. Romanowski B, Aoki FY, Martel AY, et al. Collaborative Famciclovir HIV Study Group. Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. AIDS 2000;14(9):1211-1217
74. Schacker T, Hu HL, Koelle DM, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial. Ann Intern Med 1998;128(1):21-28
75. DeJesus E, Wald A, Warren T, et al. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. J Infect Dis 2003;188(7):1009-1016
76. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001;357(9263):1149-1153
77. Mole L, Ripich S, Margolis D, Holodniy M. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis 1997;176(3):766-770
78. Delany S, Mlaba N, Clayton T, et al. Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS 2009;23(4):461-469
79. Baeten JM, Strick LB, Lucchetti A, et al. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis 2008;198(12):1804-1808
80. McMahon MA, Siliciano JD, Lai J, et al. The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation. J Biol Chem 2008;283(46):31289-31293
81. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010;362(5):427-439
82. Gallagher J. Supportive care for viral infections in cancer patients. Curr Opin Oncol 1991;3(4):643-647
83. Lazarus HM, Belanger R, Candoni A, et al. The Penciclovir Immunocompromised Study Group. Intravenous penciclovir for treatment of herpes simplex infections in immunocompromised patients: results of a multicenter, acyclovir-controlled trial. Antimicrob Agents Chemother 1999;43(5):1192-1197
84. Slifkin M, Doron S, Snydman DR. Viral prophylaxis in organ transplant patients. Drugs. 2004;64(24):2763-2792
85. Tyring S, Barbarash RA, Nahlik JE, et al. Collaborative Famciclovir Herpes Zoster Study Group. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123(2):89-96
86. Degreef H. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents 1994;4(4):241-246
87. Shafran SD, Tyring SK, Ashton R, et al. Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. J Clin Virol 2004;29(4):248-253
88. Tyring SK, Beutner KR, Tucker BA, et al. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 2000;9(9):863-869
89. Simpson D, Lyseng-Williamson KA. Famciclovir: a review of its use in herpes zoster and genital and orolabial herpes. Drugs 2006;66(18):2397-2416
90. Partridge DG, McKendrick MW. The treatment of varicella-zoster virus infection and its complications. Expert Opin Pharmacother 2009;10(5):797-812
91. Li Q, Chen N, Yang J, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2009;(2):CD006866
92. Tyring S, Belanger R, Bezwoda W, et al. A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients. Cancer Invest 2001;19(1):13-22
93. Vickrey E, Allen S, Mehta J, Singhal S. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer 2009;115(1):229-232
94. Lin E, Luscombe C, Wang YY, et al. The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother 1996;40(2):413-418
95. Lin E, Luscombe C, Colledge D, et al. Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother 1998;42(8):2132-2137
96. Shaw T, Mok SS, Locarnini SA. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepatology 1996;24(5):996-1002
97. Main J, Brown JL, Howells C, et al. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hepat 1996;3(4):211-215
98. Rayes N, Seehofer D, Bechstein WO, et al. Long-term results of famciclovir for recurrent or de novo hepatitis B virus infection after liver transplantation. Clin Transplant 1999;13(6):447-452
99. Berenguer M, Prieto M, Rayon M, et al. Famciclovir treatment in transplant recipients with HBV-related liver disease: disappointing results. Am J Gastroenterol 2001;96(2):526-533
100. Lim SG, Wai CT, Rajnakova A, et al. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut 2002;51(4):597-599
101. Lai CL, Yuen MF, Hui CK, et al. Comparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B: results of 24 weeks of therapy. J Med Virol 2002;67(3):334-338
102. Trepo C, Jezek P, Atkinson G, et al. Famciclovir in chronic hepatitis B: results of a dose-finding study. J Hepatol 2000;32(6):1011-1018
103. de Man RA, Marcellin P, Habal F, et al. A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B. Hepatology 2000;32(2):413-417
104. Manns MP, Neuhaus P, Atkinson GF, et al. Famciclovir treatment of hepatitis B infection following liver transplantation: a long-term, multi-centre study. Transpl Infect Dis 2001;3(1):16-23 (Pubitemid 32148446)
105. Saltzman R, Jurewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob Agents Chemother 1994;38(10):2454-2457
106. Loveless MS, Stephen L, Harris, John RW. Famciclovir in the management of first-episode genital herpes. Infect Dis Clin Pract 1997;6(Suppl 1):S12-S6
107. Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine (Baltimore). 1997;76(5):369-380
108. Wedemeyer H, Boker KH, Pethig K, et al. Famciclovir treatment of chronic hepatitis B in heart transplant recipients: a prospective trial. Transplantation 1999;68(10):1503-1511
109. Sacks SL, Bishop AM, Fox R, Lee GCY. A double-blind, placebo-controlled trial of the effect of chronically administered oral famciclovir on sperm production in men with recurrent genital herpes infection. Antivir Res 1994;23(Suppl 1):S72
110. Spruance SL. Prophylactic chemotherapy with acyclovir for recurrent herpes simplex labialis. J Med Virol 1993;(Suppl 1):27-32